一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
010-86108875
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook >> CAS DataBase List >> sacubitril

sacubitril

sacubitril price.
  • $406 - $2000
  • Product name: sacubitril
  • CAS: 1038924-61-6
  • MF: C17H17NO
  • MW: 251.32
  • EINECS:
  • MDL Number:MFCD26401537
  • Synonyms:sacubitril;(S)-5-[(biphenyl-4-yl)Methyl]pyrrolidin-2-one;(S)-5-([1,1'-biphenyl]-4-ylMethyl)pyrrolidin-2-one;2-Pyrrolidinone, 5-([1,1'-biphenyl]-4-ylmethyl)-, (5S)-;sacubitril ISO 9001:2015 REACH
7 prices
Selected condition:
Brand
  • Biosynth
  • Chemenu
  • Crysdot
Package
  • 1g
  • 1000mg
  • 5g
  • 5000mg
  • ManufacturerBiosynth
  • Product numberNRB92461
  • Product description(S)-5-((1,1'-Biphenyl)-4-ylmethyl)pyrrolidin-2-one
  • Packaging5000mg
  • Price$2000
  • Updated2026-06-04
  • Buy
  • ManufacturerBiosynth
  • Product numberNRB92461
  • Product description(S)-5-((1,1'-Biphenyl)-4-ylmethyl)pyrrolidin-2-one
  • Packaging1000mg
  • Price$630
  • Updated2026-06-04
  • Buy
  • ManufacturerChemenu
  • Product numberCM198982
  • Product description(S)-5-([1,1''-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95%
  • Packaging1g
  • Price$435
  • Updated2021-12-16
  • Buy
  • ManufacturerChemenu
  • Product numberCM198982
  • Product description(S)-5-([1,1'-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95%
  • Packaging5g
  • Price$406
  • Updated2026-05-26
  • Buy
  • ManufacturerChemenu
  • Product numberCM198982
  • Product description(S)-5-([1,1'-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95%
  • Packaging5g
  • Price$406
  • Updated2026-05-20
  • Buy
  • ManufacturerCrysdot
  • Product numberCD11361443
  • Product description(S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+%
  • Packaging1g
  • Price$460
  • Updated2026-05-27
  • Buy
  • ManufacturerCrysdot
  • Product numberCD11361443
  • Product description(S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+%
  • Packaging1g
  • Price$460
  • Updated2021-12-16
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Biosynth NRB92461 (S)-5-((1,1'-Biphenyl)-4-ylmethyl)pyrrolidin-2-one 5000mg $2000 2026-06-04 Buy
Biosynth NRB92461 (S)-5-((1,1'-Biphenyl)-4-ylmethyl)pyrrolidin-2-one 1000mg $630 2026-06-04 Buy
Chemenu CM198982 (S)-5-([1,1''-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95% 1g $435 2021-12-16 Buy
Chemenu CM198982 (S)-5-([1,1'-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95% 5g $406 2026-05-26 Buy
Chemenu CM198982 (S)-5-([1,1'-biphenyl]-4-ylmethyl)pyrrolidin-2-one 95% 5g $406 2026-05-20 Buy
Crysdot CD11361443 (S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+% 1g $460 2026-05-27 Buy
Crysdot CD11361443 (S)-5-([1,1'-Biphenyl]-4-ylmethyl)pyrrolidin-2-one 95+% 1g $460 2021-12-16 Buy

Properties

Boiling point :473.6±24.0 °C(Predicted)
Density :1.117±0.06 g/cm3(Predicted)
pka :16.31±0.40(Predicted)

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

Sacubitril is a neprilysin inhibitor prodrug developed by Novartis that was approved as part of an orally administered supramolecular sodium salt complex with the angiotensin receptor blocker (ARB) valsartan in the U.S. and EU in 2015. Sacubitril/valsartan (also known as LCZ-696) is a first-in-class dual angiotensin receptor blocker neprilysin inhibitor (ARNI) marketed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). It represents a novel mechanistic approach to targeting HFrEF and is the first pharmacologic agent approved for HFrEF since 2004. Sacubitril is metabolized by enzymatic conversion of the ethyl ester to the active diacid (LBQ-657, structure not disclosed), which inhibits neprilysin and prevents endogenous natriuretic peptide degradation. Neprilysin inhibitors like sacubitril are not effective as monotherapy and need to be combined with a reninangiotensin aldosterone system (RAAS) inhibitor such as valsartan. Notably, dual neprilysin and angiotensin-converting enzyme (ACE) inhibition, as in omapatrilat, was found to be associated with an increased risk of life-threatening angioedema due to increased bradykinin levels. In phase III clinical trials, sacubitril/ valsartan displayed a superior safety profile to enalapril, with a 20% decrease in heart failure hospitalizations or cardiovascular death and a 16% reduction in the risk of death from any cause. Sacubitril/valsartan is now recommended as the standard of care for HFrEF as an alternative to ACEs and ARBs.

巴楚县| 宁波市| 灌云县| 青岛市| 永清县| 定日县| 孟津县| 若羌县| 双城市| 渝中区| 延安市| 桦甸市| 临澧县| 凤山县| 镇原县| 栖霞市| 定陶县| 沂水县| 太湖县| 穆棱市| 鹤壁市| 溧水县| 明星| 库车县| 普格县| 沂南县| 大同市| 宜川县| 连平县| 虹口区| 贡嘎县| 金门县| 中江县| 汾西县| 醴陵市| 华阴市| 浮山县| 山东省| 修水县| 武鸣县| 汝城县|